Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2015 | Pages:
204 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Sanofi - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Sanofi - Product Pipeline Review - 2015', provides an overview of the Sanofi's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Sanofi's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Sanofi including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Sanofi's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Sanofi's pipeline products Reason To Buy - Evaluate Sanofi's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Sanofi in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Sanofi's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Sanofi and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sanofi - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Sanofi and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Sanofi Snapshot 6 Sanofi Overview 6 Key Information 6 Key Facts 6 Sanofi - Research and Development Overview 7 Key Therapeutic Areas 7 Sanofi - Pipeline Review 14 Pipeline Products by Stage of Development 14 Pipeline Products - Monotherapy 15 Pipeline Products - Combination Treatment Modalities 16 Pipeline Products - Partnered Products 17 Pipeline Products - Out-Licensed Products 19 Sanofi - Pipeline Products Glance 21 Sanofi - Late Stage Pipeline Products 21 Sanofi - Clinical Stage Pipeline Products 24 Sanofi - Early Stage Pipeline Products 27 Sanofi - Drug Profiles 30 (fluticasone propionate + formoterol fumarate) 30 Toujeo 32 mipomersen sodium 34 semuloparin 36 (fexofenadine hydrochloride + phenylephrine hydrochloride) 37 (insulin glargine + lixisenatide) 38 cabazitaxel 40 encephalitis vaccine 42 insulin lispro 44 lixisenatide 45 tetanus + diphtheria + pertussis (acellular) vaccine 48 fexinidazole 49 alemtuzumab 51 coltuximab ravtansine 54 ferroquine 56 isatuximab 57 plerixafor 59 SAR-125844 61 SAR-156597 62 vatelizumab 63 VerorabVax 64 GZ-389988A 65 pilaralisib 66 SAR-408701 69 SAR-421869 70 SAR-422459 71 voxtalisib 72 AVE-8112 74 SAR-113244 75 SAR-228810 76 SAR-252067 77 SAR-405838 78 SAR-405838 + pimasertib hydrochloride 79 SAR-425899 80 SAR-566658 81 ACP-002 83 ACP-003 84 ACP-004 85 AVE-3085 86 BSI-401 87 cyclohexylgriselimycin 88 Drugs for Type 1 Diabetes 89 food allergy vaccine 90 LCB-17 91 MI-51964 92 Monoclonal Antibody Conjugated 5 for Oncology 93 RDX-002 94 Recombinant Proteins for Undisclosed Indication 95 SAR-088 96 SAR-110068 97 SAR-131675 98 SAR-156497 99 SAR-184841 100 SAR-216471 101 SAR-224 102 SAR-244181 103 SAR-296968 104 SAR-396049 105 Small Molecules 1 for Tuberculosis 106 Small Molecules for Malaria 107 Small Molecules to Inhibit DGAT-1 for Metabolic Disorders 108 Small Molecules to Inhibit PI3K Beta for Oncology 109 Vasculotide 110 Labyrinthopeptine A1 111 Monoclonal Antibodies for Infectious Disease 112 SAR-405 113 Small Molecule 4 for Tuberculosis 114 Small Molecule for Calcific Aortic Valve Stenosis 115 Small Molecule for Dilated Cardiomyopathy 116 Small Molecule for Duchenne Muscular Dystrophy 117 Small Molecules 2 for Tuberculosis 118 Small Molecules 3 for Tuberculosis 119 Small Molecules to Inhibit 11 Beta-Hydroxysteroid Dehydrogenase 1 for Diabetes 120 Small Molecules to Inhibit Protein Kinase for Multiple Undisclosed Indications 121 Small Molecules to Inhibit Protein Kinase for Undisclosed Indication 122 Sanofi - Pipeline Analysis 123 Sanofi - Pipeline Products by Target 123 Sanofi - Pipeline Products by Route of Administration 127 Sanofi - Pipeline Products by Molecule Type 128 Sanofi - Pipeline Products by Mechanism of Action 129 Sanofi - Recent Pipeline Updates 133 Sanofi - Dormant Projects 161 Sanofi - Discontinued Pipeline Products 165 Discontinued Pipeline Product Profiles 167 Sanofi - Locations And Subsidiaries 177 Head Office 177 Other Locations & Subsidiaries 177 Sanofi - Key Manufacturing Facilities 195 Appendix 196 Methodology 196 Coverage 196 Secondary Research 196 Primary Research 196 Expert Panel Validation 196 Contact Us 196 Disclaimer 197
List of Tables
Sanofi, Key Information 13 Sanofi, Key Facts 13 Sanofi - Pipeline by Indication, 2015 16 Sanofi - Pipeline by Stage of Development, 2015 21 Sanofi - Monotherapy Products in Pipeline, 2015 22 Sanofi - Combination Treatment Modalities in Pipeline, 2015 23 Sanofi - Partnered Products in Pipeline, 2015 24 Sanofi - Partnered Products/ Combination Treatment Modalities, 2015 25 Sanofi - Out-Licensed Products in Pipeline, 2015 26 Sanofi - Out-Licensed Products/ Combination Treatment Modalities, 2015 27 Sanofi - Pre-Registration, 2015 28 Sanofi - Filing rejected/Withdrawn, 2015 29 Sanofi - Phase III, 2015 30 Sanofi - Phase II, 2015 31 Sanofi - Phase I, 2015 32 Sanofi - Preclinical, 2015 34 Sanofi - Discovery, 2015 36 Sanofi - Pipeline by Target, 2015 130 Sanofi - Pipeline by Route of Administration, 2015 134 Sanofi - Pipeline by Molecule Type, 2015 135 Sanofi - Pipeline Products by Mechanism of Action, 2015 137 Sanofi - Recent Pipeline Updates, 2015 140 Sanofi - Dormant Developmental Projects,2015 168 Sanofi - Discontinued Pipeline Products, 2015 172 Sanofi, Other Locations 184 Sanofi, Subsidiaries 184 Sanofi, Key Manufacturing Facilities 202
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
